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ABSTRACT
The initiation and progression of prostate cancer remain not well understood to enable development of interventional therapy. Thromboxane synthase is an enzyme downstream of cyclooxygenase, utilizing prostaglandin H to form thromboxane A 2 . Using immunohistochemistry analysis, we found that 25% of clinical prostate tumor specimens had strong expression of thromboxane synthase; 33% of cases had medium expression and 42% of cases had weak expression of thromboxane synthase. Prostate cancer cells isolated from lymph node metastasis had higher levels of thromboxane synthase expression and activity than those isolated from the primary tumor sites in an animal model. We cloned and sequenced full-length thromboxane synthase cDNA from PC-3 cells and constructed an expression vector. 
INTRODUCTION
The hemostatic system plays an important role in the regulation of tumor angiogenesis and progression. Prostate cancer is one of most common cancers affecting American men. The initiation and progression of prostate cancer remain not well understood to enable rational development of interventional therapy. In this proposal, we propose to study thromboxane synthase and its product, thromboxane A 2 , in prostate cancer progression. Thromboxane synthase is an enzyme downstream cyclooxygenase, utilizing prostaglandin H to form thromboxane A 2 . Thromboxane A 2 is a potent inducer of platelet aggregation which can subsequently lead to coagulation and thrombosis, a hematological complication affecting about 15% to 20% of cancer patients and the second leading cause of death in cancer patients. Platelet aggregation also release a plethora of angiogenesis regulators and fibrin deposition to facilitate angiogenesis and formation of tumor stroma. In addition, it has been demonstrated that thromboxane A 2 also can directly modulate endothelial cell angiogenic responses. It is our working hypothesis that TXA2 may play an important role in prostate tumor progression and that this functional role of TXA2 is achieved by modulating tumor cell motility, endothelial angiogenic responses, and platelet aggregation. TXA2 produced by PCa cells can promote PCa cell migration as an autocoid and modulate endothelial cell angiogenic responses and stimulate platelet aggregation as a paracrine factor. Platelet aggregation release various angiogenesis regulators and cause coagulation, which subsequently leads to deposition of fibrin at tumor sites. These events, collectively, promote tumor angiogenesis and growth. The proposed work will provide significant insights into how prostate cancer cells regulate cell migration and hemostatic system to facilitate tumor angiogenesis, growth, and metastasis. The knowledge obtained from the proposed work will identify key targets (TX synthase and TXA 2 receptor) to develop interventional therapy for prostate cancer, advancing the program's eventual goal to eliminate prostate cancer.
BODY OF REPORT List of Technical Objectives
Modified Task 2. Study the effect of increased expression of wild type TX synthase in DU145 cells on cell migration, proliferation, and apoptosis. a. Convert the mutated TX synthase expression construct to wild-type, through site directed mutagenesis approach. b.
Transfect Du145 cells using the new, wild-type TX synthase expression construct and study the biosynthesis of TXA2. c.
Plate the transfected DU145 cells and vector control cells and study the proliferation rate using MTS proliferation assay kit. d.
Plate TX synthase transfected DU145 cells, and their vector control, in 10 cm dishes and study whether TX synthase overexpression confers on DU145 cells resistance to apoptosis induced by COX inhibitor NS398, as assessed by DNA laddering and apoptosis induced by COX inhibitor NS398, as assessed by DNA laddering and apoptosis ELISA for DNA fragmentation. e.
Plate TX synthase transfected DU145 cells and vector control cells in fibronectin-precoated Boyden chambers for migration assay as a standard procedure.
Research Progress
When we submitted our request for a one year no-cost extension we listed Modified Task 2 above as our stated objective. However shortly after we receiving the extension we initiated a collaboration with Dr. Anthony Ashton of the Albert Einstein Medical School. Dr. Ashton had developed antibodies individually recognizing the two thromboxane receptors, i.e. TPoa and TPP3. These antibodies which were useful in immunohistochemistry gave us the unique opportunity to conduct a clinical study on expression of TPoC and TP[ in human prostate tissues. Therefore we modified our objectives to the analysis of TPcx and TPI3 expression. The results of which are presented below.
Expression of TP-beta and TP-alpha in human prostate Expression of TP-beta and TP-alpha was analyzed by immunohistochemistry in 51 radical prostatectomy specimens, which included 25 organ-confined (pT2) and 26 locally advanced diseases (16 pT3a and 10 pT3b). Of those 25 organ-confined prostate cancers, 10, 14 and 1 had a Gleason score 6, 7 and 8 respectively, whereas of those 26 locally advanced diseases, 21, 4 and I had a Gleason score 7, 8 and 9 respectively. Immunoreactivity was evaluated semiquantitatively according to staining intensity and percentage of cells stained. A staining score, which was determined by the percentage of tumor cells with moderate and strong staining intensity, was assigned to each tumor. Mann-Whitney test was used for statistical analysis and a p value of <0.05 was considered significant.
In normal prostatic glands, TP-beta was mainly expressed in the basal cells. Increased expression in luminal cells was found in areas of atrophy, basal cell hyperplasia, inflammation and transitional cell metaplasia. Significantly increased TP-beta expression was also found in high-grade prostatic intraepithelial neoplasia (Figure 1 ). The expression of TP-alpha was very focal and week in non-neoplastic prostate. In high-grade prostatic intraepithelial neoplasia, the expression of TP-alpha was variably increased (Figure 2 ). Both markers were heterogeneously expressed in prostatic adenocarcinomas. When the cases was separated into 2 groups according to pathologic stage (pT), a tendency of increased expression of both markers was noted in the advanced tumors (Table 1) . However, these differences were not statistically significant. Interestingly, when the tumors were categorized according to Gleason score, expression of both markers was significantly increased in moderately to poorly differentiated tumors (Gleason score Ž7) compared to moderately well differentiated tumors (Gleason score 6) (Table 2, Figure 1 and 2) . There was no further significar5 differences in Ihe expression of either marker between moderately poorly differentiated tumors (Gleason score 7) and poorly differentiated tumors (Gleason score 8 and higher). These results suggest that TP-alpha and TP-beta may play important roles in the initiation and early progression of prostate cancer. 
